Apnimed (APMD) Director Paul Fonteyne Receives and Transfers Derivative Shares

What Happened

• Paul R. Fonteyne, a director of Apnimed, reported a series of derivative transactions dated July 30 and August 3, 2026. The Form 4 shows zero-dollar grants and zero-dollar dispositions (derivative instruments), including total acquisitions of 185,321 derivative shares and dispositions of 140,844 derivative shares, resulting in a reported net increase of 44,477 derivative shares. All transactions are reported at $0.00 per share (no cash value shown).

Key Details

• Transaction dates and amounts: grants (A) totaling 185,321 derivative shares (including 51,890 and multiple 44,477 lots) and dispositions to the issuer (D) totaling 140,844 derivative shares (including 51,890 and 44,477 lots) on Jul 30 and Aug 3, 2026. All reported at $0.00 per share (total $0).
• Shares owned after transaction: not specified in the information provided on this summary.
• Notable footnotes:
  • F1: Common Stock was reclassified into Series A Common Stock (reclassification exempt under Rule 16b-7 and Rule 16b-3).
  • F2–F4: Describe vesting schedules for option grants (standard staged vesting: 25% after 12 months, remainder in equal quarterly or monthly installments over 36 months, depending on grant).
• Filing: Form 4 was filed on Aug 3, 2026 and reports transactions dated Jul 30 and Aug 3, 2026.

Context

• These are derivative transactions (grants and dispositions), not open-market purchases or sales. The $0.00 price and footnotes indicate reclassification and option award/vesting activity rather than a cash sale or market purchase. Such filings document changes in derivative holdings but do not by themselves indicate buying or selling sentiment like an open market trade would.